Chronic Obstructive Pulmonary Disease Treatment Market (By Drug Class: Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, Others; By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 160

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
       1.1.1. Definition of Chronic Obstructive Pulmonary Disease Treatment
       1.1.2. Market Segmentation
       1.1.3. List of Abbreviations
1.2. Summary
       1.2.1. Market Snapshot
       1.2.2. Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class
                 1.2.2.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
                 1.2.2.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Drug Class in 2017
                 1.2.2.3. Bronchodilators
                 1.2.2.4. Combination
                 1.2.2.5. Phosphodiesterase Type 4 Inhibitors
                 1.2.2.6. Mucokinetics
                 1.2.2.7. Corticosteroids
                 1.2.2.8. Others
       1.2.3. Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel
                 1.2.3.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
                 1.2.3.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Distribution Channel in 2017
                 1.2.3.3. Online Pharmacies
                 1.2.3.4. Hospital Pharmacies
                 1.2.3.5. Retail Pharmacies
                 1.2.3.6. Others
       1.2.4. Chronic Obstructive Pulmonary Disease Treatment Market by Geography
                 1.2.4.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
                 1.2.4.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
                 1.2.4.3. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
                 1.2.4.4. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
                 1.2.4.5. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
                 1.2.4.6. Middle East and Africa (MEA) Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
       2.4.1. Bargaining Power of Suppliers
       2.4.2. Bargaining Power of Buyers
       2.4.3. Threat of Substitute
       2.4.4. Threat of New Entrants
       2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
       2.6.1. Raw Material and Suppliers
       2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
       2.8.1. Player Positioning Analysis
       2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017

CHAPTER 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DRUG CLASS

4.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Drug Class
4.2. Bronchodilators
       4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Combination
       4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Phosphodiesterase Type 4 Inhibitors
       4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Mucokinetics
       4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Corticosteroids
       4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Others
       4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

5.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Distribution Channel
5.2. Online Pharmacies
       5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hospital Pharmacies
       5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Retail Pharmacies
       5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
       5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

6.1. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
       6.3.1. U.S. Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       6.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
6.4. Canada
       6.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       6.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
6.5. Mexico
       6.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       6.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

7.1. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
       7.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       7.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.4. Germany
       7.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       7.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.5. France
       7.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       7.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.6. Spain
       7.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       7.6.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.7. Rest of Europe
       7.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       7.7.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

8.1. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
       8.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Japan
       8.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5. India
       8.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.6. Australia
       8.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.6.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.7. South Korea
       8.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.7.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
       8.8.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.8.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

9.1. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
       9.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       9.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Argentina
       9.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       9.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. Rest of Latin America
       9.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       9.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

10.1. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
         10.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. UAE
         10.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. Rest of Middle East
         10.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

11.1. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
         11.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         11.3.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. Egypt
         11.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         11.4.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Africa
         11.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         11.5.2. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Orion Corporation
         12.1.1. Company Snapshot
         12.1.2. Overview
         12.1.3. Financial Overview
         12.1.4. Product Portfolio
         12.1.5. Key Developments
         12.1.6. Strategies
12.2. AstraZeneca
         12.2.1. Company Snapshot
         12.2.2. Overview
         12.2.3. Financial Overview
         12.2.4. Product Portfolio
         12.2.5. Key Developments
         12.2.6. Strategies
12.3. Mylan N.V.
         12.3.1. Company Snapshot
         12.3.2. Overview
         12.3.3. Financial Overview
         12.3.4. Product Portfolio
         12.3.5. Key Developments
         12.3.6. Strategies
12.4. BoehringerIngelheim Pharmaceuticals, Inc.
         12.4.1. Company Snapshot
         12.4.2. Overview
         12.4.3. Financial Overview
         12.4.4. Product Portfolio
         12.4.5. Key Developments
         12.4.6. Strategies
12.5. Teva Pharmaceutical Industries Ltd.
         12.5.1. Company Snapshot
         12.5.2. Overview
         12.5.3. Financial Overview
         12.5.4. Product Portfolio
         12.5.5. Key Developments
         12.5.6. Strategies
12.6. GlaxoSmithKline plc
         12.6.1. Company Snapshot
         12.6.2. Overview
         12.6.3. Financial Overview
         12.6.4. Product Portfolio
         12.6.5. Key Developments
         12.6.6. Strategies
12.7. Novartis AG
         12.7.1. Company Snapshot
         12.7.2. Overview
         12.7.3. Financial Overview
         12.7.4. Product Portfolio
         12.7.5. Key Developments
         12.7.6. Strategies
12.8. Sunovion Pharmaceuticals, Inc.
         12.8.1. Company Snapshot
         12.8.2. Overview
         12.8.3. Financial Overview
         12.8.4. Product Portfolio
         12.8.5. Key Developments
         12.8.6. Strategies
12.9. CHIESI Farmaceutici S.p.A.
         12.9.1. Company Snapshot
         12.9.2. Overview
         12.9.3. Financial Overview
         12.9.4. Product Portfolio
         12.9.5. Key Developments
         12.9.6. Strategies
12.10. Others
           12.10.1. Company Snapshot
           12.10.2. Overview
           12.10.3. Financial Overview
           12.10.4. Product Portfolio
           12.10.5. Key Developments
           12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
         13.1.1. Initial Data Search
         13.1.2. Secondary Research
         13.1.3. Primary Research
13.2. Assumptions and Scope

Cart Summary